Verrica Pharmaceuticals Inc. (VRCA) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
44 West Gay Street Suite 400
West Chester, PA 19380
United States of America (the)
Phone
484 453 3300
Website
Sector
Healthcare
Industry
Biotechnology
Employees
76
First IPO Date
June 15, 2018
| Name | Title | Pay | Year Born |
| Jayson Rieger | President, Chief Executive Officer & Director | 391,167 | 1976 |
| Noah L. Rosenberg | Chief Medical Officer | 243,316 | 1967 |
| John J. Kirby | Interim Chief Financial Officer | 532,500 | 1972 |
| Chris Chapman | Chief Commercial Officer | 635,379 | N/A |
| David Zawitz | COO, Chief Legal Officer & Secretary | 0 | 1981 |
| Eugene Scavola | Executive Vice President of Technical Operations | 0 | N/A |
| Bradley J. Catalone | Head of Drug Development | 0 | N/A |
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.